Hiru Corporation

Hiru Corporation, through its subsidiary, produces Chinese herbs for the naturopathic industry in China. It manufactures herbal supplements containing ginseng. The company sells and distributes pharmaceuticals, health and beauty products, dietary and herbal supplements, and other healthcare products. It manufactures approximately 120 extracts used in traditional Chinese medicine. Hiru Corporation sells its products through regional distributors, as well as directly to the hospitals, clinics, and pharmacies in China. Hiru Corporation was formerly known as Phoenix Restaurant Group, Inc. and changed its name to Hiru Corporation in November 2008. The company is based in Phoenix, Arizona.

Hiru Corporation trades as HIRU on OTC. The company is classified in Consumer Defensive / Beverages - Non-Alcoholic and reports in USD.

The current profile places the business in Beverages - Non-Alcoholic. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$1.69M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Hiru Corporation can be compared against peers such as Apple Rush Company, Inc., CCA Industries, Inc., Merion, Inc., Flow Beverage Corp., Full Motion Beverage, Inc., Green Globe International, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $4.42M, beta of -0.03, and return on equity of -3.3%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

HIRU currently shows total debt of $0 and beta of -0.03. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SC 13G/A (2025-08-06 00:00:00), SC 13G/A (2025-01-24 00:00:00), 8-K (2024-10-08 00:00:00), SC 13G (2024-10-07 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.waterandiceshop.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.